Loading
Diabetes Treatment and Management / Adipokines, Inflammation, and Metabolic Diseases · Journal article
Quality in Sport · August 13, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing immunometabolic mechanisms in rheumatic diseases and proposing GLP-1 receptor agonists as a therapeutic target based on mechanistic plausibility and early emerging evidence. The authors explicitly conclude that further mechanistic studies and clinical trials are needed, positioning the work as hypothesis-generating rather than evidence of clinical efficacy.
Narrative review. Studies of rheumatic diseases, immunometabolism, and GLP-1 signaling; population scope not precisely bounded.. Intervention: GLP-1 receptor agonists and GLP-1 signaling pathways in rheumatic disease contexts..
Dysregulated glycolysis, mitochondrial dysfunction, altered lipid metabolism, and hypoxia-driven signaling contribute to chronic inflammation and tissue damage in rheumatic diseases. GLP-1RAs modulate immune responses, attenuate inflammation, and improve cardiometabolic outcomes beyond glucose-lowering effects. Emerging evidence suggests potential benefits in rheumatoid arthritis, osteoarthritis, psoriasis, and other immune-mediated disorders.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize this as a mechanistic hypothesis and synthesis of early-stage evidence, not a basis for changing practice. The authors explicitly call for further clinical trials to define any therapeutic role of GLP-1RAs in rheumatic diseases.
A narrative review synthesizing mechanistic pathways and emerging evidence without primary clinical trial data, raising questions about GLP-1RA potential in rheumatic diseases rather than answering them with controlled evidence.
As stated by the source record.
Clinicians should recognize this as a mechanistic hypothesis and synthesis of early-stage evidence, not a basis for changing practice. The authors explicitly call for further clinical trials to define any therapeutic role of GLP-1RAs in rheumatic diseases.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
BackgroundRheumatic diseases are increasingly recognized as disorders driven by both immune dysregulation and profound metabolic alterations. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for obesity and type 2 diabetes, have demonstrated pleiotropic effects extending beyond metabolic control. However, the relationship between immunometabolism and GLP-1 signaling in rheumatic diseases remains incompletely understood. AimTo summarize current evidence on the interplay between immunometabolic pathways and GLP-1 signaling in rheumatic diseases. Material and methodsA narrative review of studies published between 2010 and 2026 was conducted using the PubMed, Scopus, and Web of Science databases. ResultsDysregulated glycolysis, mitochondrial dysfunction, altered lipid metabolism, and hypoxia-driven signaling contribute to chronic inflammation and tissue damage in rheumatic diseases. Key pathways involving AMP-activated protein kinase, mammalian target of rapamycin, hypoxia-inducible factor-1α, and the NLRP3 inflammasome link metabolism to immune activation. Beyond their glucose-lowering effects, GLP-1RAs modulate immune responses, attenuate inflammation, and improve cardiometabolic outcomes. Emerging evidence suggests potential benefits in rheumatoid arthritis, osteoarthritis, psoriasis, and other immune-mediated disorders. ConclusionsImmunometabolism represents a promising therapeutic frontier in rheumatology, positioning GLP-1 signaling at the intersection of metabolism and immune homeostasis. Further mechanistic studies and clinical trials are needed to define the therapeutic role of GLP-1RAs in rheumatic diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.